ECCO 2026

IL-23 - is this the good-bye from systemic therapy?

Advances in anti‑fibrotic therapy

Early treatment concepts with infliximab

What is the best post-operative strategy in CD?

Fistulizing disease - what can we do better?

Update on upadacitinib vs. risankizumab after anti-TNF…

Deeper endpoints in clincial trials and RW

Exciting new data on surgery - for all patient groups?

Long-term data on colorectal cancer risk in modern IBD…

Diet as prevention and early intervention in Crohn’s…

Molecular medicine driving treatment decisioning!?

Molecular signature–driven therapy

Should we stop thiopurines in IBD patients who are…

Stop of thiopurines in patients on subcutaneous…

What is the best treatment approach in IBD?

Top-down- versus Step-up-Therapie beim Morbus Crohn

Was ist der beste Therapieansatz bei CED?

Θα πρέπει να σταματήσουμε τις θειοπουρίνες σε ασθενείς…

LIR!C 10 yrs FUP: Is there a benefit for surgery?

Should we prevent or treat post-operative recurrence in…

Do we need immediate postoperative prophylaxis?

JAK–STAT inhibition as a therapeutic approach for…

Top-down vs. step-up therapy in CD

Long-term risankizumab persistence

Faut-il prévenir ou traiter la récidive postopératoire…

Is onmiddellijke postoperatieve preventie nodig?

Top-down vs. Step-up Therapie beim Morbus Crohn

LIR!C — suivi 10 ans: bénéfice de la chirurgie?

JAK-STAT Hemmung zur Fistel-Therapie

Steroid sparing effect of filgotinib in UC

Long term outcomes after appendicectomy in UC (5 year…

Treat-2-target strategy in UC

Combination therapy with tofacitinib and…

Pouch surgery: only for expert centers

Pouchchirurgie: enkel voor expertisecentra

Tofacitinib-Steroid-Kombination bei ASUC

ASUC: Derde‑lijn­therapie slimmer inzetten

Resultados a largo plazo tras apendicectomía en colitis…

Strategia treat-to-target nella colite ulcerosa

Long-term outcomes of IL‑23 inhibitors

Obefazimod as antifibrotic agent

Risque de cancer colorectal dans les MICI

Obefazimod come agente antifibrotico

UPA vs RISA in Crohn’s disease – a decision dilemma

Histo-endoscopic outcomes of upadacitinib in CD

Guselkumab may improve and prevent extraintestinal…

Ustekinumab is effective and safe for paediatric…

Guselkumab – does it treat only the gut?

Nicht nur im Darm – Wirksamkeit von Guselkumab bei…

Το ustekinumab είναι αποτελεσματικό και ασφαλές σε…

Guselkumab a objawy pozajelitowe

UPA vs RISA w chorobie Leśniowskiego-Crohna – sztuka…

Short-term effectiveness and safety of Mirikizumab in…

Histo-endoscopic outcomes of guselkumab in UC

Mirikizumab is able to induce disease clearence in…

Does colectomy reduce the risk of death in UC?

Early symptomatic response with IL-23 blockers

Efficacy and safety of vedolizumab + upadacitinib as…

Vedolizumab combined with upadacitinib vs Vedolizumab…

Short term transmural healing detected by US in CD…

Long-term efficacy and safety of risankizumab in UC

Etrasimod in the milder moderate UC patients

Early and durable response with guselkumab

Efficacia e sicurezza a lungo termine di risankizumab…

Frühes symptomatisches Ansprechen unter IL-23-Blockade

Efectividad y seguridad a corto plazo de Mirikizumab en…

Valutazione a breve termine della guarigione…

Vedolizumab combinado con upadacitinib vs Vedolizumab…

Est-ce que la colectomie réduit le risque de décès dans…

Efficacia e sicurezza di vedolizumab + upadacitinib…

Icotrokinra and systemic inflammatory burden in UC

Appendectomy - a new therapeutic option in UC

Impact of icotrokinra on biomarkers in UC

AGMB-129, Ontunisertib, new MoA in patients with…

The STENOVA Trial. Ontunisertib shows promising results…

Cytotoxic CD4+ accumulate in the UC but not CD mucosa…

Ontunisertib - ALK5 blockage in fistulizing CD

Ontunisertib – ALK5-Blockade bei fistulierendem Morbus…

Ikotrokinkra a stan zapalny w colitis ulcerosa

L’accumulo di cellule citotossiche CD4+ caratterizza la…

Apendektomie - eine neue Therapieoption bei Colitis…

Η μελέτη STENOVA: Το ontunisertib δείχνει υποσχόμενα…

Impact de l’icotrokinra sur les biomarqueurs dans la…

תאי B במרכז העניינים

IBDMED going global!

ADHD and autism in IBD – the same or different story?

IBDMED מעבר לאזור הים התיכון